NanoViricitudes, Inc (OTCMKTS:NNVC) Just a Hair from $1
The one-dollar level looks like a good attractor for the stock of NanoViricitudes, Inc (OTCMKTS:NNVC), a biotech company that took off truly well even outside the range of promotions. Still, NNVC is supported by regular press releases outlining the bright future of the company. NNVC added a bit more than 4% on Wednesday to stand at 99 cents, on dollar volumes exceeding $700,000.
Thus, NNVC now stands at the positions at the beginning of 2012, and is precariously close to a potential reversal. 
Still, NNVC is going strong, with only two days of selling this month and robust buying volumes that gradually led up the price from around 65 cents. 
We could say NNVC is part of the general trend of revival for small cap biotechnological companies of various quality. For this selection, the underlying financials are as follows:
- $15.4 million cash
- $17.8 million total assets
- $7.7 million total liabilities
- $3.6 million quarterly net loss
- $36 million loss for 96 months
But at least NNVC is quite far from the hype around Arch Therapeutics, Inc. (OTCBB:ARTH), a much promoted selection from the medical industry, which fizzled out on overly zealous messages, which caused investors to smell a rat and move out.
The last message for NNVC was from StockRoach.com, coming at the beginning of June. Still, the stock is very responsive to press releases. Yet the general mood of comments is rather negative, viewing this ticker as an unsustainable offer. Since then, StockRoach has moved on to another loud promotion, leaving NNVC to make it on its own.
Another recently active ticker, Nuvilex, Inc. (OTCMKTS:NVLX) is showing a similar story. The stock got boosted from 4 to 20 cents, a good run, followed by a correction and a long sideways drift. In the case of drug producers and other biomedical researchers, it is best not to be blinded by the positive news, and to stay away unless one is ready for the inevitable retreats.
